Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

Thomas R.Jeffry Evans; Masatoshi Kudo; Richard S. Finn; Kwang Hyub Han; Ann Lii Cheng; Masafumi Ikeda; Silvija Kraljevic; Min Ren; Corina E. Dutcus; Fabio Piscaglia; Max W. Sung

doi:10.1038/s41416-019-0534-2

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

Thomas R.Jeffry Evans, Masatoshi Kudo, Richard S. Finn, Kwang Hyub Han, Ann Lii Cheng, Masafumi Ikeda, Silvija Kraljevic, Min Ren, Corina E. Dutcus, Fabio Piscaglia, Max W. Sung

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Original language	English
Pages (from-to)	625
Number of pages	1
Journal	British Journal of Cancer
Volume	121
Issue number	7
DOIs	https://doi.org/10.1038/s41416-019-0534-2
State	Published - 1 Oct 2019
Externally published	Yes

Access to Document

10.1038/s41416-019-0534-2

Fingerprint

Dive into the research topics of 'Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)'. Together they form a unique fingerprint.

Cite this

Evans, T. R. J., Kudo, M., Finn, R. S., Han, K. H., Cheng, A. L., Ikeda, M., Kraljevic, S., Ren, M., Dutcus, C. E., Piscaglia, F., & Sung, M. W. (2019). Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). British Journal of Cancer, 121(7), 625. https://doi.org/10.1038/s41416-019-0534-2

Evans, Thomas R.Jeffry ; Kudo, Masatoshi ; Finn, Richard S. et al. / Correction : Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). In: British Journal of Cancer. 2019 ; Vol. 121, No. 7. pp. 625.

@article{29ccc2a23c8847bc826a3fa0c1fd959d,

title = "Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)",

abstract = "This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.",

author = "Evans, \{Thomas R.Jeffry\} and Masatoshi Kudo and Finn, \{Richard S.\} and Han, \{Kwang Hyub\} and Cheng, \{Ann Lii\} and Masafumi Ikeda and Silvija Kraljevic and Min Ren and Dutcus, \{Corina E.\} and Fabio Piscaglia and Sung, \{Max W.\}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = oct,

day = "1",

doi = "10.1038/s41416-019-0534-2",

language = "English",

volume = "121",

pages = "625",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "7",

}

Evans, TRJ, Kudo, M, Finn, RS, Han, KH, Cheng, AL, Ikeda, M, Kraljevic, S, Ren, M, Dutcus, CE, Piscaglia, F & Sung, MW 2019, 'Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)', British Journal of Cancer, vol. 121, no. 7, pp. 625. https://doi.org/10.1038/s41416-019-0534-2

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). / Evans, Thomas R.Jeffry; Kudo, Masatoshi; Finn, Richard S. et al.
In: British Journal of Cancer, Vol. 121, No. 7, 01.10.2019, p. 625.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

AU - Evans, Thomas R.Jeffry

AU - Kudo, Masatoshi

AU - Finn, Richard S.

AU - Han, Kwang Hyub

AU - Cheng, Ann Lii

AU - Ikeda, Masafumi

AU - Kraljevic, Silvija

AU - Ren, Min

AU - Dutcus, Corina E.

AU - Piscaglia, Fabio

AU - Sung, Max W.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

AB - This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

UR - https://www.scopus.com/pages/publications/85069924178

U2 - 10.1038/s41416-019-0534-2

DO - 10.1038/s41416-019-0534-2

M3 - Comment/debate

C2 - 31363170

AN - SCOPUS:85069924178

SN - 0007-0920

VL - 121

SP - 625

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M et al. Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). British Journal of Cancer. 2019 Oct 1;121(7):625. doi: 10.1038/s41416-019-0534-2